Promise Bio
AI NativePioneering epiproteomics for precision medicine
Est 2023
Pioneering epiproteomics for precision medicine
Published Sep 19, 2026
Press coverage and investor participation suggest early external interest from industry observers and strategics. However, publicly available evidence of broad adoption (published customers, independent reviews, or large-scale case studies) is limited at this stage.
| Starting Price | Not publicly listed (partner/project-based) | Typically per-sample via service providers; pricing varies by panel and provider | Typically per-sample/service; some program-specific pricing examples are publicly reported but vary by context |
| Best For | Teams seeking PTM/proteoform-centric insights from MS data for immune-mediated translational questions | Targeted protein biomarker profiling with standardized panels and workflows | High-plex protein measurement for biobank- or cohort-scale profiling |
| Key Strength | Focus on PTMs and proteoform interpretation using analytics on MS data | Standardization and broad adoption in translational research; established ecosystem | High multiplexing and established assay footprint |
| Key Weakness | Limited public validation artifacts and limited third-party reviews; security/compliance not clearly documented publicly | PTM-level resolution is not the core value proposition; constrained by panel design | Methodological differences (aptamer-based) vs MS; program and pricing complexity |
—
Promise Bio’s value proposition centers on PTM/proteoform-level interpretation applied to standard MS datasets. Buyers should evaluate whether PTM-derived signals provide incremental predictive or mechanistic value over abundance-based panels or very high-plex approaches.
Versus Olink: Olink typically provides standardized assays and has broad adoption in translational biomarker studies; selection decisions should consider whether PTM-level resolution is necessary for the specific MoA or biomarker objective.
Versus SomaScan: SomaScan focuses on very high multiplexing of protein abundance measurements; comparative pilots should test whether PTM features provide complementary or superior predictive signal for a given endpoint.
Versus Seer Proteograph: Seer focuses on enabling deep proteomic profiling through sample-prep workflows; a buyer could combine Seer-like sample workflows with third-party analytics, including PTM-focused analysis, depending on integration details.